

CONTEMPORARY TECHNOLOGIES IN CHRONOPHARMACEUTIC DRUG DELIVERY SYSTEM

Abstract

Traditional drug delivery methods aimed for a consistent or sustained medication output to maximize treatment efficacy while minimizing side effects. These dosage forms release medications in a controlled or varied manner. Illnesses are treated by administering drugs to patients in a variety of traditional dose patterns. All these dosage patterns should always be administered monotonously for retaining the drug concentration in a therapeutically effective spectrum. Chronotherapeutics, a type of drug delivery system, has become increasingly important in the treatment of chronic diseases in recent years. Today's environment necessitates chronopharmaceutical formulations that increase patient compliance, optimize medicine distribution at the target site, and minimize side effects to reduce mortality rates. A mechanism in which a medicament has been distributed rapidly after a specified lag interval or time gap in compliance with the circadian rhythm of sickness conditions is known as pulsatile drug release. Pulsatile medication delivery is becoming more prevalent these days. The main benefit of this method of the medication delivery system is that the substance is only aired when it is required. Because of this, the risk of developing drug resistance, which is common in both preparations for both conventional and sustained release, is minimized. In addition, certain anticancer medications are quite hazardous. In both traditional and sustained release therapy, these medicines cause serious complications. There are now a plethora of FDA-approved chronotherapeutic medications on the market. This treatment is most useful when a long-term effect is just not necessary and medications are harmful. The most important aspect of this formulation's development is determining the circadian rhythm or an appropriate criterion that would set off the drug's release.

KEYWORDS: Chronotherapeutics, Hypertension, Circadian rhythm, pulsatile devices, OROS delivery, Formulations

Introduction

Oral administration of drugs to accomplish systemic impacts of disease such as hypertension is the most efficient remedy of administration. Systems for administering drugs orally account for around half of all drug delivery systems now on the market, and these approaches have a distinct value in terms of patient compliance and convenience of delivery. Traditional drug delivery methods aimed for a consistent or sustained medication output to maximize treatment efficacy while minimizing side effects. These dosage forms release medications in a controlled or varied manner. Illnesses are treated by administering drugs to patients in a variety of traditional dose patterns.⁽¹⁾ All these dosage patterns should always be administered monotonously for retaining the drug concentration in a therapeutically effective spectrum. Controlled distribution medication keeps the drug at a steady level rather than delivering it as and when it's needed. Conventional dosage formulations are inadequate to meet the needs of conditions if disease symptoms arise in a specific duration of day or night. To minimize the frequency of dosing and enhance patient adherence, modified-release formulations are required. Resistance, tolerance to drugs, and activation of the physiological systems because of the prolonged consistent drug concentration in the body are some of the issues associated with modified dosage form formulations.

In both health and disease, all functions in human are highly ordered in time as biological rhythms of various periods. Chronobiology deals with the internal biological clocks and the time. Chronopharmacology study the effect of biological timing on drug. Advances in chronobiology and chronopharmacology recommended drug delivery design based on the circadian rhythm. The chronopharmaceutical drug delivery systems deliver the drug over a set period of time based on the underlying activities of a disease. These drug delivery systems are designed to deliver the drug at a predetermined point of time. Pulsatile dose formulations can help in the time programmed delivery of a drug. When steady plasma drug levels are not sought, nor is an ideal therapy regimen impact is obtained from a regularly varying drug concentration, pulsatile dose forms are beneficial.⁽²⁾ Arthritis, asthma, cardiovascular diseases, peptic ulcer, hypercholesterolemia, diabetes mellitus, attention deficit syndrome are

some of the diseases necessitate chronotherapeutic approaches in management. ⁽³⁾ Here we discuss about the diseases and the effect of circadian rhythm and the chronopharmaceutical drug delivery systems.

Need of the chronokinetic drugs

The circadian time structure has received the greatest attention and is crucial in medical practice and patient therapy. Circadian rhythms play a role in the incidence of significant medical events such as myocardial infarction and stroke, as well as the expression and severity of chronic illness symptoms such as allergic rhinitis, asthma, and arthritis. Both physiological and biochemical rhythms have an impact on how patients respond to drugs, diagnostics, and therapy. The synchronization of disease pathophysiology and drug delivery is the basis of chronotherapy. Time specified delivery of drugs synchronized with biological rhythm significantly improves the therapy outcome. Control of adverse effects of the drug is one of the advantages of chronokinetic drugs, especially narrow therapeutic window drugs. ⁽⁴⁾ They reduce the frequency of drug administration and minimize the risk of toxicity. Patient compliance and a better therapeutic outcome are the benefits of chronokinetic drugs. ⁽⁵⁾

Chronopharmaceutics drug delivery system intended for antihypertensive agents

A rise in blood pressure is thought to be responsible for 7.5 million deaths worldwide, accounting for approximately 12.8 percent of overall deaths. This translates into 57 million DALYs (disability-adjusted life years), or about 3.7 percent of all DALYs. High blood pressure is, therefore, a significant potential component for coronary heart diseases, such as ischemic and hemorrhagic stroke. Blood pressure values have been correlated to a greater incidence of stroke and coronary heart disease consistently and beneficially. The probability of cardiovascular disease multiplies with each 20/10 mmHg elevation in blood pressure in specific age groups, starting at 115/75 mmHg. In conjunction to coronary heart disease and stroke, the consequences of high blood pressure include heart disease, peripheral arterial disease, renal disease, ocular hemorrhage, and vision deterioration. The lowering of cardiovascular problems is linked to managing diastolic and systolic blood pressure till it is less than 140/90 mmHg. ⁽⁶⁾

According to the World Health Organization, Hypertension affects 1.13 billion people globally, about two-thirds of them residing in low- and middle-income countries. Hypertension was diagnosed in one out of every four men and one out of every five women in 2015. Only around one out of every five hypertensive persons has their health in check. Worldwide, high blood pressure is the major driver of death. One of the worldwide non communicable disease targets is to reduce the incidence of hypertension by 25% by 2025.

Today's environment necessitates Chrono pharmaceutical formulations that increase patient compliance, optimize medicine distribution at the target site, and minimize side effects in order to reduce mortality rates. A mechanism in which a medicament has been distributed rapidly after a specified lag interval or time gap in compliance with the circadian rhythm of sickness conditions is known as pulsatile drug release. ⁽⁷⁾ Long-term treatment can lead to drug resistance, which can have harmful repercussions. The possibilities are limited since the proper medication concentration for particular times is available. ^(2,3) This technique is favorable as a result of the drug's significant metabolic first-pass and is directed to a particular location in the gastrointestinal track to accomplish the therapy objective.

Pulsatile Drug Delivery System (PDDS)

Pulsatile devices are getting prominence as they administer the medication to the optimal targeted site at the appropriate period and in the appropriate dose, allowing for spatial and temporal administration while also boosting patient compliance. In order to meet the requirement of quick medication release after a lag time, a pulsatile delivery system was designed. Within establishment of pulsatile medication release, the primary factor to consider is the circadian rhythm. When consistent drug release, zero order release of drugs, for example, also isn't preferred, the pulsatile delivery method can be highly useful. Because it is unaffected by pH, enzymes, or gastrointestinal motility, the pulsatile delivery system has been identified as a time-controlled release mechanism. ⁽⁸⁾

PDDS can be used to treat diseases that have a circadian rhythm underlying pathogenesis. It has been discovered that diseases have characteristic cyclic rhythms, and that pacing treatment regimens correctly can improve therapeutic outcomes in certain chronic disorders. Chronotherapeutic is a therapy strategy in which drug availability in vivo is scheduled in accordance with cyclic rhythms of drug-related biological processes to maximize benefit while limiting risk.




Fig.1: Diseases that necessitate PDDS are depicted in a circadian rhythm diagram. ⁽⁴⁾

Time-controlled pulsatile release (regime with a solitary or several components), intrinsic stimulation driven release, as well as pulsatile release systems driven by external stimuli are the three primary classes of PDDS based on the pulse regulation of drug release. PDDS can also be divided into three categories based on the dosage form: tablets, capsules, and pellets. The cup and the core pills are suitable for the chronotherapeutics system.

Vascular reactivity and capillary resistance are significantly greater in the early hours and reduces later during the day in cardiovascular disease; platelet agreeability is enhanced, resulting in blood hypercoagulability; as a result of this reaction, the probability of myocardial infarction and unexpected cardiac death is higher early in the morning. Heart attacks are five to six fold higher to strike between the hours of 1 to 5 in the early morning and studies indicate that early heart attacks are more serious than those that strike later in the day. High blood pressure is usually the first symptom of cardiovascular disease.

Table:1 The effect of circadian rhythm on physiological activity.

S.No	Physiological activity	Influences in activity
1	Thermoregulation	Sleep deprivation, elevated cognition
2	Respiration	Sleep deprivation, elevated cognition
3	Blood pressure	Sleep deprivation, elevated cognition
4	Growth hormone	11 p.m. rise in secretion
5	Adrenaline	11 p.m. rise in secretion
6	Heart rate	Sleep deprivation, elevated cognition
7	Catecholamines	Significant raise in the morning
8	Agreeability of plasma	Significant raise in the morning
9	Activation of fibrinolytic enzymes	Reduced in the morning
10	Secretion of gastric acid	Significant raise in the evening
11	Gastric emptying	Significant raise in the morning

Pulsatile delivery methods are divided into two categories: time-controlled and site-specific. The first group's release is mostly influenced by the system, whereas the second group's release is primarily influenced by the physiological conditions in the gastro intestinal tract, such as pH or enzymes. ⁽⁹⁾ The word "Chrono pharmaceuticals," which is a mix of chronobiology and pharmaceuticals, is related to pulsatile medication delivery. Biological rhythms as well as its processes have been discussed in chronobiology. There are three sorts of mechanical rhythms in our bodies. The term "circadian" comes from the Latin words "circa" which means "around" and "dies" which means "day." ^(10,11) Circadian rhythms in digestive, liver, kidney, and other body systems and their functions are crucial for treatments, such as deciding when to deliver medication based on pharmacokinetics, effect duration, efficacy, side effects, and favorable results. ⁽¹²⁾

Diseases with existing circadian rhythms

The disorders that have subsequently been targeted for pulsatile medication delivery have enough empirical support to justify the use of a timed pharmaceutical drug delivery system over traditional drug administration. ⁽¹³⁾ These illnesses include, among others, nighttime asthma, arthritic, duodenal ulcer, cancer, cardiovascular disease, diabetic, hyperlipidemia, and neurological issues.

Bronchial asthma

It's distinguished by airway inflammation, which causes the lower respiratory tract to be hyper responsive to numerous environmental stimuli.⁽¹⁴⁾ In asthmatic individuals, airway resistance rises gradually during night. This type of asthma, also known as nighttime asthma, is marked by an increase in symptoms, airway reactivity, and/or lung function.⁽¹⁵⁾ During the day, antigen activates mast and eosinophil cells to release pro-inflammatory mediators, which leads to exacerbation of edema, smooth muscle bronchospasm, contraction, and over activation of mucus glands, resulting in mucus hypersecretion of the lung's restricted airways. Because bronchoconstriction and clinical signs intensification follow a circadian pattern, it is a great candidate for chronotherapy.⁽¹⁶⁾

Bronchial asthma has a diurnal cycle, with symptoms peaking at night and early in the morning. Anti-asthmatic medicine dosing at night has been shown to be beneficial in bronchial asthma investigations. A solitary dosage of the majority of the pharmaceuticals now used for asthma chronotherapy at night helps patients adhere to their medications and manage their asthma better. Chronotherapy is necessary and helpful for Nocturnal Bronchial Asthma because of the day-night cycle and circadian rhythm interdependence.^(16,17) Chronotherapy is gaining popularity because it allows doctors to provide drugs at certain times based on the disease's pathophysiology, which improves patient treatment efficacy and compliance. The purpose of bronchial asthma chronotherapy is intended to produce the optimal prospective outcomes: less asthma indications, the peak flow levels at their finest, the least number of medicine adverse effects, and the retention of regular or slightly elevated pulmonary function, lifestyle, exercise, and sleep in asthmatic patients⁽¹⁸⁻²⁰⁾. Anti-inflammatory medication to manage airway inflammation, bronchodilator 2 agonist to ease bronchospasm and bronchoconstriction, and corticosteroid medication for particularly extreme forms of BA are some of the medications typically used for chemotherapy for asthma⁽²¹⁻²³⁾. Synthetic glucocorticoids have been used as a short-term "burst" to achieve swift control of an asthmatic exacerbation, as well as protracted avoidance of symptoms in serious persistent asthma; inhibition, regulation, and inversion of inflammation⁽²⁴⁾. Chronotherapy with inhaled corticosteroids (ICS) is a highly efficient anti-inflammatory treatment for the protracted management of chronic asthma. Inhaled corticosteroids can lessen or abolish the requirement for oral steroids⁽²⁵⁾.

The most widely administered corticosteroids for adult bronchial asthma are first-generation aerosol corticosteroids, such as beclomethasone, budesonide, flunisolide, fluticasone, and triamcinolone⁽²⁶⁾. These medications minimize hyper responsiveness of the airways to antigenic as well as other asthma stimuli by inhibiting the production of cytokines that cause airway inflammation^(27, 28). **Tulobuterol, a long-acting beta2-adrenergic receptor agonist transdermal patch (Hokunalin Tape, patent: WO2005046600A2) for chronotherapy, was designed and developed by Abbot Japan Co., Ltd.** This transdermal patch provides delayed release of the medicine for nocturnal asthma chronotherapy when placed at night. This 2 agonist's transdermal preparation was created to avert a quick elevated serum tulobuterol levels, as well as adverse symptoms such as palpitation and tremor that can occur when taken orally^(29,30). **Uniphyll® extended-release tablets manufactured by Purdue Pharmaceutical Products L.P. (patent; US 8431,553 B2) containing theophylline is used as an oral bronchodilator in asthma patients.**

Allergic rhinitis

Sneezing, sinus rhinorrhea, itchy red eyes, nasal itching, and difficulty breathing are all allergic rhinitis indicators⁽³¹⁾. Each symptom was shown to happen more consistently preceding breakfast as well as in the morning, and less frequently in the afternoon. Allergic rhinitis can exhibit itself in two stages: early (In a few minutes) & late (within hours) (sustaining beyond 12-16 hours). The production of Prostaglandins, histamine, cytokines, TNF-A, chemotaxis factors and other substances causes sneezing, nasal irritation, and rhinorrhea in the early stages. Late phase is characterized by circulating leukocytes, T cells, and eosinophils proliferation, adherence, and incursion resulting in nasal obstruction and blockage as a result of the worsening of nasal, sinus inflammatory conditions as well as upper respiratory tissues.⁽³²⁾

Pain

One amongst the most significant treatment goals is pain management⁽³³⁾. The greatest threshold was recorded at the completion in terms of resting time, whereas the lowest had been recorded well at conclusion of a interaction phase. The plasma concentrations of individuals having rheumatoid arthritis had higher levels of interleukin-6 and C- reactive protein follow a diurnal cycle⁽³⁴⁾. In addition, nociceptors are activated by opioid peptides such as 5-hydroxytryptamine, bradykinin, glutamate, NO, substance P, cytokines, and prostanoids⁽³³⁾. In a rat model, the proportion of substance P in the brain is greatest at night as contrasted to daytime. Endogenous opioid peptide levels are greater in the morning and significantly decrease in the late afternoon in those of neonates and human adult participants, according to research. Osteoarthritis patients experience reduced discomfort in the daytime and more anguish at bedtime. Patients suffering from rheumatoid arthritis experience discomfort which rises during early hours and gradually diminishes in the later period of the day. Finger swelling and joint soreness are two of the symptoms⁽¹²⁾. Patients with gastroesophageal reflux disease experience agony at night⁽³³⁾. Renal colic, on the other hand, has a morning peak regardless of gender or the existence or lack of noticeable kidney stones. The type of

analgesics used and how they are administered are determined by the nature and length of the pain. Anti-epileptic, local anaesthetics, and tricyclic antidepressants are employed to treat nociceptive pain, whereas anticonvulsants, paracetamol, NSAIDs, and morphinomimetics are used to treat neurogenic pain.

Duodenal ulcer

In most duodenal ulcer patients, secretion of stomach acid is greatest in the late afternoon while decreases mostly in early hours^(12, 34, 35). The occurrence of perforation of an ulcer was evaluated (circadian), weeklong (circaseptan), and annual (circannual) period impact by one group of investigators⁽³⁶⁾. Overall, a consistent and rather constant circadian rhythm has been discovered throughout seasons, decades, and days of the week. Perforations in the intestines had a primary rise about midday, as well as a subsequent rise towards fortnight, while duodenal perforations had the largest percentage in the afternoon. In most subgroups, the circannual pattern for duodenal ulcer perforation was defined by the 6-month cycle, with considerably greater prevalence during May to July as well as November and December. Although no circaseptan rhythm was discovered, Thursday – Friday had a much greater occurrence than Sunday – Monday. **Gaster® tablet, a Famotidine delivery system manufactured by LTL Pharma Co., Ltd. support the chronotherapy in ulcer patients.**⁽³⁷⁾

Cancer

There are several clock genetic traits associated in the stimulation of transcription and post transcription processes, as well as the inhabitation of regulatory loops in mammalian cells that create circadian oscillation⁽³⁸⁾. CLOCK: BMAL1 or NPAS2:BMAL1 protein dimers, in particular, are important for the transcription of the clock genes Per and Cry. In a few mouse models, although, the clock genes Per1, Per2, Bmal1, and Rev-erb have been reported to be expressed. The desynchronization of specific tumor cells that form a solid tumor may cause clock gene-related rhythm changes at the tissue level.

Such a situation is caused by a variation of minutes or hours in each cell's intrinsic rhythm from its neighbours. Reduced expression of Per1, Per2, or Per3 genes at a single time point in contrast to reference tissue further supports a change in the molecular clock of human malignancies. Furthermore, cancer patients have a larger blood flow to the diseased location than the rest of the body⁽¹³⁾. Animal studies have also revealed that the rate of survival fluctuates depending on the anticancer medications' circadian dosage schedule⁽³⁸⁾. When a combination of 6-mercaptopurine and methotrexate was given in the evening instead of the morning, the percentage of patients who survived was nearly quadrupled⁽¹²⁾. Another group of researchers investigated the effect of continuous 5-fluorouracil (5-FU) infusion with circadian regimens of 5-FU administration, which exhibit peaks at 4 a.m., 10 a.m., 4 p.m., or 10 p.m.^(9,39). According to the findings, the cytotoxic effect of 5-FU on circadian delivery is minimal. Blood flow fluctuation at the rat's subcutaneous tumour location was also studied on a daily basis⁽⁴⁰⁾.

The results showed that tumour arterial circulation had been considerably maximum at night when compared during the day. While there was no significant variations between the day and night groups of rats in average arterial pressure, cancer growth, or body mass. Normal tissue blood flows such as the subcutis, liver, kidney, cortex, bone marrow, and tumour tissues (SLC) had been examined during the day and at night⁽⁴¹⁾. Rats were employed as the test animals. There were no substantial differences in average blood flow between two distinct time zones in all normal tissues. Blood flow in tumour tissue, on the other hand, was much greater during the late night when compared to during the dawn. These data indicate that blood flow at the tumour site has a circadian pattern.

Cardiovascular diseases

Vascular reactivity and capillary resistance were more prevalent in the dawn and decline eventually during the day in cardiovascular disease. In the morning, platelet aggregability increases and fibrinolytic activity decreases, resulting in hypercoagulability of the blood. As a result, the risk of myocardial infarction and sudden cardiac death is higher between the hours of 10 a.m. and 12 p.m.⁽⁴¹⁾. The described blood pressure in ambulatory blood pressure measurement exhibits a considerable diurnal fluctuation. Peripheral variables like race, sexuality, tone of the autonomic nervous system, vasoactive substances, hematological, and nephro variables all influence this variation. Increased heart rate, blood pressure, autonomic tone imbalances, and circulating levels of catecholamines that control cardiac arrhythmias all display significant diurnal variation and contribute to the emergence of the circadian pattern of cardiac arrhythmias⁽⁴²⁾. Atrial arrhythmias appear to have a diurnal pattern, with higher frequency during the day and lower frequency at night, and the aberrant foci appear to be subjected to the same long-term autonomic regulation as normal pacemaker tissue. According to the research, ventricular tachyarrhythmias have a late morning peak in individuals who have had a myocardial infarction in the distant past and an afternoon peak in those who have had a recent myocardial infarction. Myocardial ischemia, angina pectoris, acute myocardial infarction, and sudden cardiac death are likewise unevenly distributed throughout the course of a 24-hour period, with higher-than-expected incidents occurring in the late afternoon or early evening⁽⁴³⁾. The circadian time of administration has been demonstrated to affect the pharmacokinetics and pharmacodynamics of several oral nitrates, calcium channel blockers, and α -adrenoceptor antagonist medicines. Some of the available chronotherapeutic delivery systems available in the market for the therapy of hypertension

are specified here. Verelan® PM (verapamil) extended-release capsules manufactured by RECRO Gainesville (US6500459B1) are prescribed for hypertension. It reduces the elevated blood pressure during the morning period.⁽⁴⁴⁾ Cardizem® LA-extended-release tablets contain Diltiazem HCL and Verapamil HCL, is used in the chronotherapeutic treatment of hypertension. InnoPran® XL-extended-release capsules of Propranolol HCL Verapamil HCL is a circadian aligned formulation for night time administration and to provide maximum effect in the morning.⁽⁴⁵⁾

Diabetes

Circadian cycles of insulin requirement and its activities are commonly asked questions in the instance of type I diabetes from a physiological and clinical standpoint^(46, 47). Insulin is usually delivered in a pulsatile pattern, however it can also be irregular. Insulin can have a cyclic rhythmicity of 8-30 minutes, indicating that it is performing at its best. Insulin release in the basal mode has both stimulatory and inhibitory effects on B cells. Stress hormones, cortisol, epinephrine, and growth hormone may impair target cell sensitivity to insulin action and hyperglycemia, while intrinsic rhythmicity, dehydration, and sustained insulin cessation may stimulate a secondary feedback signal on insulin release, that can aim to boost blood sugar levels. The modulators of insulin release and action are segregated in a circadian pattern, and the mode of insulin release is influenced secondarily. As a result, any change in plasma insulin concentration between a daily maximum and minimum, aside from its short-term rhythmicity, must be considered a complex secondary circadian rhythm. It's because of the variable secondary insulin resistance that occurs early in the morning and late in the afternoon.⁽⁴⁸⁾

Hypercholesterolemia

During cholesterol production, a circadian rhythm occurs. Cholesterol synthesis is often higher at night than during the day. It differs from person to person at times. The maximum production occurs in the early morning, 12 hours after the last meal. Evening dose of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors was found to be more effective than morning dosing in studies. The rate-limiting enzyme HMG-CoA has a greater activity at night⁽⁴⁹⁾. The diurnal changes, on the other hand, are caused by the regulating enzyme's periodicity or deterioration. Zocor® tablets, a controlled release simvastatin is prescribed for patients with hypercholesterolemia helps in the chronologically aligned drug delivery. Lipovas® tablet is another formulation of simvastatin (Cipla Ltd) used in hypercholesterolemia chronotherapy.⁽⁵⁰⁾

Sleep disorder

Many biological signalling systems, such as sleep disorders in the central and autonomous nervous systems, have a complicated time structure with rhythm and pulsatile changes in multiple frequencies.

Each person's sleep requirements are usually consistent. Despite the fact that there is a lot of variance between people⁽⁵¹⁾. A rhythmic (circadian) mix of changes in physiological biochemical and physiological processes characterises sleep. A range of illnesses can occur when a circadian rhythm is disrupted or when particular processes during sleep are aberrant. Delayed sleep phase syndrome, for example, is characterised by severe sleep-onset insomnia⁽¹¹⁾. Sleep is normally not feasible until 3 a.m. or later, or until waking up at the customary time is extremely difficult. The ability to adjust to the circadian rhythm varies among individuals as well. In managing with various sleep disorders, identifying individual variation is half the battle.⁽⁵²⁾

Epilepsy

Some types of epileptic seizures may also be influenced by the circadian rhythm⁽⁵³⁾. In several experimental animal models, the impact of the circadian rhythm on epilepsy of some partial seizures has been discovered. The approach for measuring the human circadian rhythm is also looked into. Behavioral chronobiology allows for the detection of possible new regulatory processes relating to epilepsy's core mechanisms⁽⁵⁴⁾. Because of this, the circadian psychophysiological pattern of epilepsy reveals dynamic biological systems that suggest certain endogenous processes of intermodulation between observation and seizure susceptibility. Furthermore, the application of chronobiologic principles to epileptic behaviour suggests the emergence of new heuristic elements in comparative Psychophysiology.⁽⁵⁵⁾

Alzheimer's disease

Patients with alzheimer's disease experience changes in their circadian rhythm⁽⁵⁶⁾. Individuals with Alzheimer's disease had lower diurnal motor behavior, a greater proportion of nighttime activity, worse inter-day motor activity stability, and a later activity acrophase (peak time) than healthy people. Alzheimer's disease causes neurodegeneration in the suprachiasmatic nucleus, which disturbs the brain's circadian cycles. Patients with this condition have a greater core body temperature. In this

condition, the circadian irregularities are evident alongside cognitive and functional decline. There have been no other modifications assessed.⁽⁵⁷⁾

Parkinson's disease

Parkinson's disease causes autonomic dysfunction, which causes many changes in the circadian rhythm of blood pressure, as well as increased diurnal blood pressure fluctuation and postprandial hypotension⁽⁵⁸⁾. However, the presence of a circadian rhythm in this condition has yet to be determined. Clinical data demonstrate daily oscillations in motor activity patterns, but it's impossible to predict the impact on the course of the disease and the following functions of medications.⁽⁵⁹⁾

Coagulation disorder and thrombosis

Life depends on the fluidity and preservation of blood inside the circulatory system⁽⁶⁰⁾. The hemostatic system is formed by the actions and interactions of multiple variables that combine to generate these dual roles. Many components of the circulatory and haemostatic systems, such as muscle cells, the aorta, peripheral vascular muscle, and endothelium, have been revealed to have a circadian rhythm.⁽⁶¹⁾

Circadian rhythm changes in time structure can cause hypercoagulability and thrombosis, or hypocoagulability and bleeding. Peripheral resistance, blood flow, blood viscosity, blood pressure, and heart rate are all factors that affect haemostasis. During the afternoon, peripheral vascular resistance reduced, resulting in an increase in blood flow in diurnally active personnel. In the morning, the vasomotor tone of coronary and peripheral arteries, as well as the vasoconstrictor response to adrenaline, are higher than in the afternoon. - thromboglobulin has a peak concentration at 6 a.m. and a low concentration between noon and midnight. Factor VII has a strong diurnal fluctuation, peaking between 8 a.m. and noon, while its antigen level does not.⁽⁶²⁾

Factor IX is likewise said to be at its height around 9 a.m. Natural coagulation inhibitors such as protein C, protein S, and antithrombin have their highest concentrations at 6 a.m. and their lowest concentrations between noon and midnight. Although fibrinolytic systems show rhythmic changes, these may differ at the local tissue level.⁽⁶³⁾

Infectious disease

Changes in the occurrence of infectious diseases over time are well-known⁽⁶⁴⁾. Fever related to bacterial illnesses is more likely in the evening, whereas fever owing to viral infections is much more likely in the daytime, and influenza is epidemic throughout the winter season. In both the northern and southern hemispheres, it was found that morbidity and mortality were highest in the winter and lowest in the summer. The weight of nasal discharges is peak in the morning in cold patients, then decreases during the day until increasing slightly in the late evening. Though the cause of individual infectious disease seasonal patterns is complicated because several factors are implicated, seasonal cycles in infectious diseases are commonly credited to seasonal variation in weather/atmospheric circumstances, pathogenic or incidence of casual pathogens, and/or variations in host behavior.⁽⁶⁵⁾

Furthermore, the immune system, as well as the central nervous system, autonomous nervous system, endocrine glands, peripheral endocrine tissues, such as the intestinal tract and adipose tissue, and the immune system, have a variable time configuration with rhythms and pulsatile variants in multiple frequencies⁽⁶⁶⁾. Biological indices such as cortisol, catecholamines, and melatonin have all changed. In diurnally active people, intraocular pressure, which would be a diagnostic hallmark of glaucoma, is high around 2 and 4 a.m. and least in the late afternoon⁽¹¹⁾.

Many endocrine factors require rhythmicity to have an effect. The rhythmic variability of a hormone or associated messenger determines its impacts and potency on a target tissue at multiple places⁽⁶⁷⁾. Melatonin promotes the nighttime drop in body temperature that may be caused by vascular melatonin receptor stimulation, which causes peripheral vasodilation. Because of the nighttime reduction in body temperature, sleep is easy to come by. Plasma concentrations of prolactin show pulsatile episodic hormone secretion characteristics that are dominant after ultradian rhythms and circadian oscillation. During rapid eye movement sleep, the majority of the hormone is separated.

Regardless of the time of day, sleep beginning is accompanied with an upsurge in prolactin production during daytime sleep, but the intensity of the prolactin increase during daytime sleep is usually lower than during nocturnal sleep. Thyroid stimulating hormone is released in separate pulses as well. The incidence and extent of diseases have a circadian rhythm as well. At night, gout, gallbladder, and peptic ulcer attacks are more common.⁽⁶⁸⁾

In the morning, depression is more intense. Migraine headaches are usually brought on by rapid eye movement episodes that occur during sleep or early in the morning. The following markers of various diseases are useful in the design of a pulsatile drug delivery system because they will trigger the release of the medicine after a predetermined time interval. It can be used for single dose as well as multiple dosing. The importance of rhythms, particularly circadian rhythms, in physiology,

pharmacology, molecular biology, and health sciences has grown dramatically in recent years ⁽⁶⁹⁾. When drugs are swallowed, injected, infused, or administered in any other way, the circadian time when they are taken, injected, infused, or applied in any other way seems to be a very significant indicator of its efficacy and safety. The circadian timing of drugs may even play a role in patient survival in life-threatening situations.

Formulative chronopharmacology Review

Osmosis-based system

The capsule is covered with a selectively permeable membrane in these systems. The capsule contains an insoluble plug, an osmotically active agent, and a medication formulation. When the partially permeable of the capsule shell comes into touch with GI fluid, gastric fluid can pass through. As a result, the plug swells, causing osmotic pressure.




Fig.2. Drug delivery with an erodible coating layer in a pulsatile drug delivery system is depicted schematically. ⁽⁷⁰⁾

When such pressure surpasses the membrane's tensile properties, it bursts, and the time it takes for the membrane to rupture is characterized as lag period. After a certain amount of time has passed, the plug is ejected, allowing the medicine to be released. Barzegar-Jalali and colleagues Hard gelatin capsules loaded containing acetaminophen, sorbitol as just an osmotic agent, and sodium dodecyl sulphate as a release promoter were developed as an osmotic capsule. The capsule shell was sealed with white bees wax and covered with partially permeable cellulose acetate comprising lipophilic plasticizer (castor oil) ⁽⁷⁰⁾ when a semipermeable membrane comes into touch with water, it allows water to pass through and increases the osmotic pressure within the shell. It raises hydrostatic pressure, causing the plug to fall outside the shell and the medicine to be released.

Linkwitz et al. used expandable orifice technology in their research ⁽⁷¹⁾ the medicine is given through the capsule's wall via this device that is in the type of a capsule. It is so tiny that the drug flow through the aperture is almost zero in a relaxed state. The flexible barrier is expanded when pressure is created within the shell. As a result, the orifice widens significantly from time to time allowing the medicine to be released in a pulsatile way. Up a different osmotic delivery capsule demonstrated pulsatile active medication release ⁽⁷²⁾

Rather than chemical compositions, the structure of pulsatile medication administration can be constructed. Within the capsule, a moveable barrier has been placed to separate the medicine from the osmotically active substances. Inside the capsule, impediments are put at regular intervals. Until enough pressure develops within the chamber to counteract the resistance, every barrier keeps the partition immobile. The partition then proceeds to the next point, where it is immobilised once more. During the advancing movement of the partition, the medication is released. Niwa et al. employed ethyl cellulose capsules for osmotic-based time-specific medication release with in colon ^(73, 74). The impact of internal diameter on drug release was investigated by varying the thickness of the ethyl cellulose capsule body. Towards the base of the capsule structure, there were countless tiny holes. The hydroxyl propyl cellulose with low substituents was retained at the bottom of the body. A mixture of medication, bulking agent, and fluorescein was put above the hydroxyl propyl cellulose. After that, a powerful ethyl cellulose solution was used to cap and seal the capsule. Water permeates the capsule through micro pores when it comes into touch with G.I. fluid, causing the hydroxyl propyl cellulose to swell. As a result, internal osmotic pressure rises, producing capsule shell rupture.

The development of a once-daily controlled-onset extended-release (COER-24) dosage of verapamil hydrochloride depends on osmotic pumping ⁽¹⁰⁹⁾. COER-24 was a bipartite core tablet with an expandable polymeric compartment and a medication

compartment, designed using OROS® Push-pull™ technology. A semi-permeable layer was applied to the core, with laser-drilled orifices linking the medication tablet to the outer medium. A hydrophilic layer is placed across the center as well as the outside membrane to extend the time between release and the commencement of the delay (fig. 2). The active substance dissolved when exposed to water, and the push chamber began to enlarge. As a result, the medication solution was continuously pumped out via the semipermeable film's orifices. Verapamil was found to be released in a sustained manner over a period of 4-6 hours, with an excellent in vitro-in vivo connection ⁽¹²⁰⁾. Clinical investigations verified COER-24's potential for satisfying the well-established chronotherapeutic criteria of cardiovascular disease ⁽¹²¹⁾. This technology is used in the chronopharmaceutical product Covera-HS (Pfizer, Patent: US6500459B1), which is currently on the market.

System based on capsule

The Pulsincap system is a capsule-based pulsatile system that is widely utilised. R.P. Scherer International Corporation, based in Michigan, developed it ⁽⁷⁴⁾. It comprises of a drug reservoir enclosed in an insoluble capsule. The drug substance is sealed inside the capsule body with swellable hydrogel plugs. Hydrogels of various viscosity grades, such as hydroxypropyl methyl cellulose, poly methyl methacrylates, poly vinyl acetate, and poly ethylene oxide, are utilised to create such plugs. Lag time is determined by the length of the plug. The capsule shell's soluble cap, which is dissolved in the presence of dissolving or gastric juice, locks the entire system together. After ingesting gastric media, the plug swells as well as exerts itself beyond the capsule, releasing the medication.

Bussemer et al. created and tested a pulsatile drug delivery device based on a drug-filled hard gelatin capsule with a swelling layer and an exterior water-insoluble but porous coating ⁽⁷⁵⁾. The lag time increases as the diameter of the external coating film increases. With the inclusion of a hydrophilic pore forming and an increase in the diameter of the bulging layer, it can be reduced to a minimum.




Fig:3 System based on capsule

Krogel and Bodmeier tested a pulsatile delivery system relying on an impervious capsule shell with an erodible plug ⁽⁷⁶⁾. The medication and excipients were first poured into the insoluble capsule body. Simultaneous interpretation or coagulating a meltable plug inside the capsule aperture were used to make the Plug. The lag time is determined by the plug's disintegration or erosion time. They changed the plug's composition later on ⁽⁷⁷⁾. Pectin and pectinase enzyme are used to make this plug. Because the enzyme is present in the plug, it degrades it. Super disintegrants have been employed in the formulation of capsule-based systems that include a medication, a swelling agent, and a rupturable polymer matrix ⁽⁷⁸⁾. The swelling compound is swelled to the point where the polymeric film is totally ruptured. All solid and liquid medication formulations can be delivered using this technique. ^(79, 80)

System with eroidable, soluble or rupturable membrane

A different notion has been used in this case. A dissolving or prone to erosion barrier is applied to a drug reservoir. The medicine is discharged from the reservoir when the barrier dissolves or erodes. The time clock ® system is made up of a solid dosage form covered with lipid barriers made up of caruba wax and bees' wax, as well as surfactants like polyoxyethylene sorbitan monolate^(81, 82). At the aqueous environment, the layer erodes or emulsifies in a timeframe proportionate to the diameter of the coating, exposing the core for dispersion. In existence of intestinal enzymes, mechanical action of the stomach, or gastro-intestinal pH did not appear to alter the lipophilic film redispersion in a research with human volunteers, and the lag time seemed irrespective of gastric residence duration⁽⁷³⁾. Because the lag time rises as the layer thickness increases, such approaches are ideal for water soluble drugs.

The main benefit of this system is that it is simple to manufacture and does not require any special equipment; yet, lipid-based systems can have a lot of in-vivo variation (e.g. food effects). Since water permeates and breaks the medicine in erosion-controlled systems, the drug may be released prematurely. The solubilized medication disperses out via the barrier layers as well as releases over time without eroding or dissolving the barrier layer completely. As a result, the medication release is slowed in a pulsatile manner.

A drug-containing core is covered with lipophobic swellable hydroxypropylmethyl cellulose (HPMC) in the chronotropic system⁽⁸³⁾. After a predetermined amount of time, the barrier coating dissipates or diminishes. The thickness of the surface coating as well as the viscosity grade of HPMC can actually affect the lag time before release of drug out from reservoir-type⁽⁸⁴⁾. Furthermore, using an exterior gastric resistance enteric membrane frequently can help to address the variation in gastric emptying and generate colon-specific release⁽⁸⁵⁾. The drug was released following a lag time through the in vitro release profiles of enteric coated anti-prime tablet, and the pharmacokinetic results corroborated a lag period earlier to the availability of significant levels of drug in saliva. The lag times and the amount of hydrophilic retarding polymer applied had a good correlation. Both pills and capsules can be used with this technique.^(86, 87, 88)

Two drug-containing layers were separated by a drug-free gellable polymeric matrix in a three-layered tablet^(89, 90). Mostly in existence of dissolution media, the initial dose out from uncoated layer is released swiftly. The dosage is wrapped on three sites with impervious ethyl cellulose as well as the top section was left uncoated. The gellable barrier layer then makes contact with the dissolving media. Because of the contact with water, this barrier transforms into a viscous gel, decreasing its resistance qualities. The length of time it takes for water to travel through the barrier layer is determined not only by its composition, but also by its thickness.⁽⁹¹⁾

Due to consistent gastric emptying, reduced chance of dose dumping, adjustable release patterns, and enhanced bioavailability with reduced inter and intra structural variability, multiparticulate systems are attracting a lot of interest in pulsatile drug administration⁽⁹³⁾. The core containing the medicine is coated with a polymeric coating that erodes over period as a lag time⁽⁹²⁾. This approach has been used to coat the core of pellets containing pharmaceuticals with hydroxypropyl methyl cellulose (HPMC). Ethyl cellulose (EC), hydroxypropyl methyl cellulose phthalate (HPMCP), and a plasticizer diethylphthalate made up the outermost erodible layer. Because the EC to HPMCP ratio was 1:1, holes formed as a result of HPMCP flushing inside the intestinal region. To obtain a lag period of 3.5 to 5 hours and, most likely, to prevent early drug release, a significant covering level (weight gain of about 40%) is required. Patients improved significantly in a clinical trial using capsules containing pellets and the medication nizatidine. Mini tablets were made in a different way by pressing elevated viscosity HPMC and microcrystalline cellulose in varying ratios to achieve different lag times.^(94, 95)

To achieve the appropriate lag durations, eroding systems typically require thick eroding layers, particularly when such pellets are small. The issue is that water-soluble drugs can sometimes leak through the inflated barrier. On either hand, due to persisting barrier components, medication release after a lag period is sustained. In contrast to an erodible or swellable coating system, a rupturable membrane system relies on the coating disintegration to release the medication. Effervescent excipients, swelling agents, or osmotic pressure can all be used to provide the pressure required for the coating to rupture. This system is protected by a membrane that is water insoluble but permeable.

Many gadgets have been coated with an interior swellable layer and an outside rupturable layer in recent years. The thickness of the swellable layer controls drug release, however the coating layer's elasticity as well as tensile strength may also play a role. In a tablet core coated with ethyl cellulose, Krogel et al. utilised an effervescent combination of citric acid with sodium bicarbonate⁽⁹⁶⁾. When carbon dioxide reacts with water, it causes the outer layer to break, allowing the medication to escape. A drifting pulsatile system is another name for this system. Tartaric acid can be used in place of citric acid. The lag time is determined by the firmness of its core tablet, not the coating thickness. This method can be applied to systems with several units. The swellable layer is applied to non-pareil sugar seeds in multiparticulate systems, accompanied by a water-resistant but porous layer⁽⁹⁷⁾. Based on the overall weight of the core, 5 to 60% of the medication is contained in the core. To quickly break the outer membrane, super disintegrants such as sodiumcarboxy methyl cellulose, sodium starch glycolate, L-hydroxypropyl cellulose, and polymers such as poly vinyl acetate, poly acrylic acid, and polyethylene glycol are commonly utilised. Varying the coating thickness and adding high volumes of lipid soluble plasticizer with in the outer layer might modify the lag time. A considerable portion of osmotic agent is used to achieve rapid medication release.

System with change in membrane permeability

Pellet cores covered with amino-methylacrylate copolymer and containing medication and succinic acid yielded a sigmoid kind of releasing pattern^(98, 99). The succinic acid is dissolved by the water in the medium. The polymer film's permeability is increased by the medication and the acid environment inside. Actually, the presence of various counter-ions in the medium can alter the porosity as well as water uptake by acrylic polymers carrying quaternary ammonium groups⁽¹⁰⁰⁾. The polymer side chain of Eudragit RS 30D comprises a positively polarised quaternary ammonium group, which is invariably accompanied by negative HCl counterions. The hydrophilic character of the ammonium group improves the contact of the polymer with water, resulting in a change in permeability and regulated water penetration of the active core. The drug permeability of the Eudragit film is also influenced by a little volume of sodium acetate in the pellet core. This causes the complete dose to be released in a matter of minutes. This system is utilised to create a core that contains acid.

Different chronopharmaceutical technologies that have recently been made available

OROS technology

Chronset™ is now a patented OROS delivery device that delivers a bolus medicine dose to the gastrointestinal system in a time- or site-specific way. It's purely an osmosis-based mechanism. The active medication is stored in a reservoir that is enclosed by a selectively permeable membrane that has been laser perforated with a delivery aperture and then formed into a tablet. This tablet is made up of two layers: one medication surface as well as another osmotically active ingredient. The osmotic agent transforms between non-dispensable onto dispensable viscosity when it comes into contact with GI fluid. As a result of the osmotic agent's pump effect, active medication is pushed out of the channel. It is commonly employed in the development of **extended-release tablets⁽¹²¹⁾**. Procardia XL®, Ditropan XL® and Concerta® are some of the examples of OROS systems.

Oros oral drug delivery technology

Ceform technology

It creates pharmaceutical substance microspheres that are equally sized and formed. This method is based on "melt-spinning," which involves processing solid substrate (i.e. biodegradable polymer/bioactive agent combination) using a mixture of temperature, heat fluxes, mechanical stimuli, flow, and flow rates. The microspheres are virtually completely spherical, with a diameter of roughly 150-180mm, and may hold a large amount of medication. Pills, capsules, suspensions, effervescent tablets, and sachets are just a few of the dosage forms that the microspheres can be employed in. The microspheres can be coated including an enteric coating for controlled release or mixed as a fast/slow release mixture.

Contin technology

A molecular coordination complex is formed between cellulose polymer and then a nonpolar solid aliphatic alcohol. A polar solvent is used to dissolve the polymer at first. An aliphatic group may be substituted with alcohol if desired. This alcohol is preferably applied as a melt to the solvated polymer. It then forms a coordination complex that can be used as a scaffold in controlled release formulations because of its consistent porosity that can be modified. It can also be used to create controlled-release tablets. This method has a high level of control over drug delivery into the bloodstream, lowering the risk of undesired side effects.

Diffucaps technology

This technique consists of a capsule-based system including one or even many drug-containing components (e.g. beads, pellets, granules etc.). Each bead has a pre-programmed quick or sustained release profile, as well as a lag time. It has already been addressed in a system having a membrane part that is erodible, soluble, or rupturable. **AMRIX (Cyclobenzaprine) is a delayed release capsule developed based on Diffucaps technology which is used in muscle spasms.**

Chronotopic technology

This is also considered in the perspective of a membrane system that's erodible, soluble, or rupturable. It's basically a drug-filled core with a release-controlling coating on top. The internal drug formulation has included solitary as well as various dosage types including tablets as well as capsules, minitabets and pellets.

Egalet technology

It has a delayed release since it is made up of an impenetrable layer containing two lag plugs enclosing an active drug plug in the centre. The medication is released after the inner plugs have eroded. The lag time is determined by the time it takes to dissolve the inner plugs. The shells are made of a mixture of pharmaceutical excipients, including polymers like poly-ethylene oxide, and

plasticizers (such as cetostearyl alcohol). The matrix of the plugs is made of a mixture of gradually compostable polymer (e.g. ethylcellulose) as well as plasticizers (such as cetostearyl alcohol) (PEO).

Codas technology

The CODAS (Chronotherapeutic Oral Drug Absorption Device) is a multiparticular approach for bedtime dosage. A non-enteric coating is put to drug-loaded beads in this case to postpone the release of the medicine for up to 5 hours. A blend of water-soluble as well as water-insoluble polymers is used in this release control. When the water-soluble polymer in this dosage pattern comes into contact with fluid, it progressively dissolves and pores form on the coated layer. The medicament diffuses thru the holes that arise. The controlled release method of verapamil is maintained by a water-insoluble polymer serving as just a barrier. pH, posture, and diet have no effect on the rate of release. **Verelan® PM release verapamil after 4-5 h of administration. The dosage form was designed based on the Codas technology**

Geoclock technology

Geomatrix technology is used to develop the concept. For continual medication release in this technique, a multilayered technology was initially advocated. One or both bases are partly covered with an active core or hydrophilic matrix. The core hydration mechanism is adjusted, and the outer layer susceptible for drug release is reduced. Its barrier layer swells to become a gel in the presence of dissolution media. Its gelling layer is not degraded; instead, it functions as a regulating membrane that regulates the release process. Instead, the erodible surface is gradually removed from the dissolving solvent. As the active core erodes, more planar surface of the active core is exposed to the outside environment for longer periods of time, facilitating drug release. **Lodotra™ developed based on Geoclock technology is Nitec's single-pulse delayed-release tablet available.**

Port technology

The PORT (Programmable Oral Release Technology) system is a specially coated, encapsulated technology that allows for numerous medication releases. It has a polymeric core that is coated with a rate-controlling, semipermeable polymer. To provide consistent controlled release from the dosage form, poorly soluble medicines can indeed be coated with solubilizing agents. The gelatin capsule is treated with a semipermeable, rate-controlling polymer in capsule form. Inside the capsule shell, the active medication is combined with an osmotic agent. The capsule shell is sealed by a water-insoluble stopper. Depending on the situation, an immediate release chamber can be incorporated ^(101, 102, 103,104).

Three dimensional printing (3dp) technology

It's a complicated oral dose administration technique that's new. It's made using a solid free-form construction technique. Internal geometries with complex internal geometries, changing densities, diffusivities, and chemical properties are beneficial in the design of such a device. Three-dimensional printing technology has been utilised to create complex dosage forms such as immediate-extended-release tablets, pulse release, breakaway tablets, and twin pulsatory tablets. Diclofenac sodium was printed in two separate regions on the enteric dual pulsatile tablets, which were made up of one uninterrupted enteric excipient phase. In vitro, these samples revealed two surges of releases with a 4 hour lag time between them. TheriForms' technology is based on this technique. It also is a microfabrication technique that functions similarly to a "inkjet" printer. It's a computer-aided design and production process that's totally integrated. Before the actual application of the preparation process, products can be designed as three-dimensional models on a computer screen.

Timerx technology

It's a controlled release device made of hydrogel. With zero order to chronotherapeutic release, this technology can help. By changing molecular interactions, it can provide varied release kinetics. The "molecular engine," according to the author, eliminates the need for sophisticated processing or unique excipients, allowing desired drug release patterns to be "factory configured" after a straightforward formulation creation process. Basically, xanthan and locust bean gums are combined with dextrose in this technology. In the presence of water, the physical interaction between these components creates a strong, binding gel. Its degree of water penetration from the gastrointestinal tract into the TIMERx gum matrix, which swells to create a gel and then releases the active therapeutic component, controls drug release.

Physico-chemical modification of the API

To achieve a chronopharmaceutical effect, physico-chemical properties of the API (active pharmaceutical ingredient) such as solubility, drug lipophilicity, partition co-efficient, crystalline form, membrane permeability, melting point, and so on can be modified by introducing new substitutions to the original structure. The maximum plasma concentration of a medication (T_{max}) changes depending on the parent compound's physiochemical modification. The T_{max} of lovastatin is 2 hours, but the T_{max} of simvastatin is 4 hours. Pulsatile medication delivery can also be achieved using the pro drug method. Lactone prodrugs like

lovastatin & simvastatin are converted to potent hydroxyl acid molecules in the liver. Lactones are indeed water soluble than various statins since they are lactones. Pepcid® tablets, Zocor® tablets, and Gaster® tablets are some of the chronotherapeutic systems work based on Physico-chemical modification of the API.⁽¹²²⁾

Chronomodulated infusion pump

These devices are light in weight and have high accuracy drug delivery values. An insulin-containing implantable infusion pump is surgically implanted inside the left top or bottom quadrant of the abdomen's subcutaneous tissue (above or below the belt). The insulin is delivered intraperitoneal via a catheter that runs from the pump thru the muscle layer and into the peritoneal cavity, where it floats freely. It is replenished once monthly or every three months by putting a needle into the pump via the skin under the supervision of a physician. Melodie™, Rhythmic™, Panomat™ V5 and Synchroned™ are some of the examples.

Microchip with controlled release

The solid-state silicon microchip is a microfabrication process that uses micrometre scale pumps, valves, and flow channels to distribute active medication in a pulsatile way. It can release single or several chemical substances in a controlled manner depending on the situation. The electro-chemical dissolution of anode membranes covering a micro reservoir packed with chemicals in solid, liquid, or gel form provides the basis for the release mechanism. Proof-of-principle release investigations with a prototype microchip employing gold as the electrode material and saline as the release medium indicated regulated, pulsatile release of chemical compounds with this device.

Chronopharmacokinetics: the drugs circadian rhythm

Chronopharmacokinetics is the analysis of observed changes in pharmacokinetics and hence considers the impact of administration time on these several processes. Sequential differences in absorption of drugs as from gastro-intestinal tract (because of changes in gastric acid output and pH, mobility, gastric emptying time, and digestive blood circulation), plasma protein binding and drug distribution, drug metabolism (temporal variation in enzyme activity, hepatic blood flow), and renal drug excretion can all be affected by temporal variations (due to variation in glomerular filtration, renal blood flow, urinary pH tubular resorption.) As a result, the timing of drug administration is a major source of variance that must be included in kinetic investigations, necessitating the use of specific chronokinetics methodology^(105, 106, 107)

When do we need chronokinetic studies?

There are some instants in which chronokinetic study is needed:

- Whenever necessary, each day pharmacokinetic fluctuations may be to blame for time-dependent alterations within medication effects (For example, some antimicrobials are much more efficient at certain times of the day),
- Whenever the drug's therapeutic range is limited, or when disease symptoms are clearly related to the 24-hour clock. (Examples include nocturnal asthma, angina pectoris, myocardial infarctions, and ulcer disease)
- When it comes to therapeutic action of a medicine is well connected with its plasma concentrations, even though the latter is circadian phase dependent.
- Whenever a medicine has a major detrimental effect which can be prevented or diminished by changing the time of delivery (e.g. aminoglycosides, nephrotoxicity).

Chronokinetic drugs:

Antihypertensive drugs: Within 24 hours of the day, nearly all physiological functions and pathological events, including the cardiovascular system, show repeatable rhythmic alterations. Antihypertensive drug effects on blood pressure and heart rate rhythms in addition varies with the duration of day, according to clinical chronopharmacological investigations. Daily variations in the kinetics of propranolol, oxprenolol, nifedipine, verapamil, and other drugs were also identified in chronopharmacokinetic studies. C_{max} was greater and/or T_{max} was narrower following dawn administration of these lipophilic medicines than nighttime dosing. Regardless than whether or not daily fluctuations in the kinetics were discovered, the dose-response association has mostly been time-dependent^(108, 109).

Antibiotics: The kinetics of antimicrobial medicines have been found to vary over time in many investigations. The period that perhaps the levels of antibiotics remain higher than the MIC (T>MIC) is the greatest critical element to ascertain the in vivo effectiveness of antibiotics such as beta-lactams which have lethal effects independent of concentration in vitro, according to experimental animal models. As a result, regular changes in pharmacokinetics may be to blame for chemotherapeutic effect impairment. When low-susceptibility microorganisms are engaged in the infectious process, this is critical⁽¹¹⁰⁾. Another crucial component of antibiotic chronokinetics is that, as we saw with aminoglycosides, not just efficacy of the medicine but even its

toxicity can change influenced by the time during the day. The following are the most notable findings from antibiotic chronokinetics studies:

Aminoglycosides: While aminoglycosides were administered in the midst of the experimental animals' rest time, the toxicity was at its peak, whereas as they were medicated in the course of the active process, the toxicity was at its lowest. The renal function toxic effects of aminoglycosides can be decreased by delivering the medicine with a single shot per day while Patients are engaged, according to numerous studies and evidence in the current literature (at day time). The working mechanics underlying the temporal variance in aminoglycoside kidney toxicity remain unknown⁽¹¹¹⁾.

Gentamicin: The efficacy and toxicology of gentamicin differed over course of a 24-hour period, with the efficacy being highest when the drug's toxicity was lowest. Thus, giving gentamicin early or late in the day in humans may lower kidney toxicity and boost the effectiveness of such antibiotics⁽¹¹¹⁾.

Tobramycin: As tobramycin is given at 0200 h (night period), the CLT and AUC were much greater than that as tobramycin being administered at 1400 h (day period)⁽¹¹⁰⁾.

Amikacin: In humans, amikacin revealed greater kel values in the day than that of the night.

Ceftriaxone: In rats, total clearance of ceftriaxone fluctuates throughout the day, peaking during dark (active) period and declining during the light (relaxation) period⁽¹¹¹⁾.

Ciprofloxacin: The proportion of ciprofloxacin removed in urine in people was higher when the antibiotic was administered at 1000 hours as while it was delivered at 2200 hours.

Valporic acid: At the absorption phase after oral treatment, mean absolute VPA levels in plasma were considerably greater in the daytime than the night. In the morning, C_{max} was greater, t_{max} was shorter, and the absorption rate constant (k_a) was larger than in the evening, despite no differences in other pharmacokinetic variables between the morning and evening trials.

Sumatriptan: Sumatriptan is the medicine of choice for migraine treatment, because migraine is an illness with symptoms that occur at regular intervals, chronotherapy may be helpful in addressing the problem. Following the 0700h injection, the mean peak serum concentration Following the administration at 7:00 a.m. and 01:00 pm, the mean area under serum concentration time curve from zero to the last time point (AUC_{0-t}), the area under the serum concentration time curve from zero to infinity (AUC_{0-infinity}), and the area under the first movement curve (AUMC) were considerably larger after the 1900 h treatment. The mean oral clearance and apparent volume of distribution were considerably lower after the 0700 h administration than after the 1900 h administration. The differences could be attributable to changes in the degree of absorption over time and/or changes in hepatic flow on a daily basis⁽¹¹²⁾.

Cyclosporine: One study looked at the pharmacokinetics of cyclosporine in five pancreatic transplant patients. The reduced apparent clearance between the night time over the day time results in a somewhat enlarged area under the concentration-time curve in these patients. After the dusk treatment, there was a considerable delay in mean residence time, as well as the night time area under the moment curve was greater than the dawn value. We suggest three chrono pharmacokinetics dosing approaches that change the dusk dosage delivery schedule or transfer the regular amount to achieve equal cyclosporine exposure during activity and resting times. These trends and discrepancies point to the need for a more advanced time-dependent cyclosporine dosage strategy to balance dawn and dusk medication exposure and optimize immune suppression⁽¹¹³⁾.

Methotrexate: Six children with leukemia were given a methotrexate dose at 10 in the morning and 9 in the night in a study. As a result, plasma clearance dropped significantly at night. The fundamental reason of these changes (among others) would be differences in passive tubular reabsorption caused by the urine pH rhythm. A strong diurnal regularity of methotrexate serum levels was reported in two pigs at 01:00 in the afternoon in another animal (4 Pigs) investigation⁽¹¹⁴⁾.

Nsaid: Ketoprofen: When ketoprofen was given in the morning, the rate of absorption was likewise observed to be increased⁽¹¹⁵⁾.

Indomethacin: When the medicine was administered at 07:00 or 11:00 h instead of 15:00, 19:00, or 23:00 h, the peak concentration was significantly greater and earlier⁽¹¹⁶⁾.

Current situation and future scope

Pulsatile medication delivery is becoming more prevalent these days. The main benefit of this method of the medication delivery system is that the substance is only aired when it is required. Because of this, the risk of developing drug resistance, which is common in both preparations for both conventional and sustained release, is minimized. In addition, certain anticancer medications are quite hazardous. In both traditional and sustained release therapy, these medicines cause serious complications^(117, 118, 119). There

are now a plethora of FDA-approved Chrono therapeutic medications on the market. This treatment is most useful when long-term effect is just not necessary and medications are harmful. The most important aspect of this formulation's development is determining the circadian rhythm, or a appropriate criterion that would set off the drug's release. Another issue is the lack of adequate rhythmic biomaterial that must be degradable, compatible, and rhythmically sensitive to certain biomarkers. Another significant issue is regulatory. It is challenging to demonstrate Chrono therapeutic benefits in clinical settings during the preapproval phase. The FDA now largely depends upon the establishment as well as execution of risk mitigation systems as a strategy for allowing pulsatile medication administration to uncover circadian rhythm with an appropriate system anywhere throughout the universe to be approved. Due to some unique characteristics such as low dumping of doses, medication adherence, as well as the preceding criteria, such administration becomes a pioneer technique to provide restorative drugs in the future.

Conclusion

Oral pulsatile delivery has gotten a lot of attention in the last decade, notably due to its propensity applicability for satisfying chronopharmaceutical needs connected to prevalent infection with varied circadian symptoms. The literature's description of a wide range of oral pulsatile delivery systems demonstrates the presences of a keen curiosity about the branch of pharmaceuticals. True, the study of periodic rhythms in a growing variety of diseases, the convergence of Chrono therapeutics techniques, and a rising recognition of the importance of medication adherence are all probably to bolster endeavors in research in the organization, execution as well as assessment of these systems. However, for the proposed delivery systems to succeed, flexibility, novelty, a complete absence of stringent regulatory requirements, and the existence of human proof-of-concept the outcomes also seem to be believed to be critical. To ascertain the drug-delivery strategy, dosage, and delivery time, optimize favored and/or minimize negative impact, knowledge of I circadian period configuration as well as dials which govern this, (ii) cycles in disease mechanisms or there are 24 hour rhythms in disorder frequency of underlying health circumstances, and (iii) Chrono pharmacology (chronokinetics and chromodynamics) of treatments is typically required for disease chronotherapy.

COMPETING INTERESTS DISCLAIMER:

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

Reference

1. Ballesta A, Innominato PF, Dallmann R, Rand DA, Lévi FA. Systems Chronotherapeutics. *Pharmacol Rev*: 69; 2017. Pg.161-199.
2. Bussemer T, Peppas NA, Bodmeier R. Evaluation of the swelling, hydration and rupturing properties of the swelling layer of a rupturable pulsatile drug delivery system. *Eur J Pharm: Biopharm* 56; 2008. pg. 261-270.
3. Philip AK, Philip B. Chronopharmaceuticals: hype or future of pharmaceuticals. *Curr Pharm Des*: 17; 2011. Pg. 1512-6.
4. Smolensky MH, Peppas NA. Chronobiology, drug delivery, and chronotherapeutics. *Adv Drug Deliv Rev*: 59; 2007. Pg. 828-51.
5. Bruguerolle B. Chronopharmacokinetics. Current status. *Clin Pharmacokinet*: 35; 1998. Pg. 83-94.
6. Bowles NP, Thosar SS, Herzig MX, Shea SA. Chronotherapy for Hypertension. *Curr Hypertens Rep*: 28; 2018. pg. 97.

7. Manuntikumar B Mehta, Sandeep V Nathwani, Sonlwalla MM. Pulsatile Drug Delivery System: Advanced and novel approach. *Mintage Journal of Pharmaceutical and medical sciences*. Vol3. Suppl 1.Feb 2014.
8. Ciancia S, Cafarelli A, Zahoranova A, Menciassi A, Ricotti L. Pulsatile drug delivery system triggered by acoustic radiation force. *Front. Bioeng. Biotechnol.* 17; 2020. Pg. 317.
9. Youan BC. Chronopharmaceutical drug delivery systems: Hurdles, hype or hope?, *Adv. Drug Delivery. Rev.* 62; 2010 pg.898-903.
10. Rosenberg GD, Simmons DJ. Rhythmic dentinogenesis in the rabbit incisor: circadian, ultradian and infradian periods, *Calcified tissue Int.* 32; 2006 pg. 29-44.
11. Smolensky MH, Peppas NA. Chronobiology, drug delivery and chronopharmaceuticals, *Adv. Drug Deliv. Rev.*; 2007. Pg. 828-851
12. Khan Z, Pillay V, Choonara YE, du Toit LC. Drug delivery technologies for chronotherapeutic applications, *Pharm. Dev. Technol.* 14; 2009. Pg. 602-612.
13. Belgamwar VS, Gaikwad MV, Patil GB, Surana S. Pulsatile drug delivery system, *Asian J. Pharm.* July- September; 2008. Pg.141-145.
14. Smolensky MH, Lemmer B, Reinberg AE. Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma, *Adv. Drug Deliv. Rev.* 59; 2007. Pg. 852-882.
15. Lemmer B. Chronobiology: drug delivery and chronotherapeutics, *Adv. Drug Delivery. Rev.* 59; 2007 pg. 825-827.
16. Waldman-Wagner C. Asthma Care and Patient Education: The Nurse's Role, Allen & Hanburys, Research Triangle Park, NC; 1990.
17. Lewis SM, Collier IC, Heitkemper MM. *Medical Surgical Nursing: Assessment and Management of Clinical Problems*, 4th edition. Mosby, St. Louis; 1996.
18. Smolensky MH, D'Alonzo GE. Progress in the chronotherapy of nocturnal asthma, in: Redfem PH, Lemmer B (Eds), *Physiology And Pharmacology of Biological Rhythms, Handbook of Pharmacology*, vol.125, Springer-Verlag, Heidelberg; 1997. Pg.205-249.
19. Darzen JM. Bronchial asthma, in: Baum GL, Crapo JD, Cili JB. Karlinsky (Eds), 6th ed., *textbook of Pulmonary Diseases*, vol.II, Lippincott-Raven, Philadelphia; 1997. Pg.791-805.
20. Mandal AS, Biswas N, Karim KM, Guha A, Chatterjee S, Behera M, Kuotsu K. Drug delivery system based on chronobiology- a review, *J. Control. Release* 147; 2010.pg. 314-325.
21. Alessandra Maroni, Lucia Zema, Maria Dorly Del Curto, Giulia Loreti, Andrea Gazzaniga. Oral pulsatile drug delivery: rationale and chronopharmaceutical formulations, *Int. J. Pharm.* 398; 2010. Pg. 1-8.
22. Zuzana Diamant, Diderik Boot J, Christian Virchow J. Swimming up 100 years of asthma, *Respir. Med.* 101; 2007. Pg. 378-388.
23. Vianna EO, Martin RJ. Recent innovations in asthma therapy, *Drugs Today (Barc.)* 34; 198. Pg. 341-351.
24. Harter JG, Reddy WJ, Thorn GW. Studies on an intermittent corticosteroid dosage regimen, *N. Engl. J. Med.* 296; 1963. Pg.591-595.
25. McFadden ER. When to use high-dose inhaled steroids, *J. Respir. Dis.* 12 (11); 1991. Pg. 1005-1012.
26. Dyer MJ, Halpin DM, Stein K. Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone versus inhaled fluticasone for chronic asthma in adults: a systematic review, *BMC Fam. Pract.* 7; 2006. Pg. 34.
27. Barnes PJ. Effect of corticosteroids on airway hyperresponsiveness, *Am. Rev. Respir. Dis.* 141; 1990. Pg.70-76.
28. Barnes PJ. Inhaled glucocorticoids for asthma, *N. Eng. J. Med.* 332; 1995. Pg.868-875.

29. Horiguchi T, Kondo R, Miyazaki J, Fukumoto K, Torigoe H. Clinical evaluation of a transdermal therapeutic system of the beta2-agonist tulobuterol in patients with mild or moderate persistent bronchial asthma, *Arzneimittelforschung* 54; 2004. Pg. 280-285.
30. Buriko N, Miyata M, Endo M, Fukuoka Y, Suyama H, Nakazaki H, Igawa K, Shimizu E. Alteration of the circadian rhythm in peak expiratory flow of nocturnal asthma following night time transdermal beta2-adrenoreceptor agonist tulobuterol chronotherapy, *Chronobiol. Int.* 22; 2005. Pg.383-390.
31. Storms WW. Pharmacologic approaches to daytime and nighttime symptoms of allergic rhinitis. *J Allergy Clin Immunol*: 114; 2004. Pg. S146-53.
32. Nakao A, Nakamura Y, Shibata S. The circadian clock functions as a potent regulator of allergic reaction. *Allergy*. 2015 May;70(5):467-73.
33. Bruguerolle B, Labrecque G. Rhythmic pattern in pain and their chronotherapy, *Adv. Drug Deliv. Rev.* 9; 2009. Pg. 883-895.
34. Saitoh T, Watanabe Y, Kubo Y, Shinagawa M, Otsuka K, Ohkawa SA, Watanabe T. Intragastric acidity and circadian rhythm, *Biomed. Pharmacother.* 55; 2000. Pg. s138-s141.
35. Moore JG, Halberg F. Circadian rhythm of gastric acid secretion in men with active duodenal ulcer, *Dig. Dis. Sci.* 31; 1986. Pg. 1185-1191.
36. Svancs C, Sothorn RB, Sorbye H. Rhythmic patterns in incidence of peptic ulcer perforation over 5.5 decades in Norway, *Chronobiol. Int.* 15; 1998. Pg. 241-264.
37. Choudhary D, Goykar H, Kalyane D, Desai N, Tekade RK. Dose, dosage regimen, and dose adjustment in organ failure. In *Biopharmaceutics and Pharmacokinetics Considerations 2021*. pg. 29-82. Academic Press.
38. Levi F, Focan C, Karaboue A, de la Valette, Focan-Henrard D, Baron B, Kreutz F, Giacchetti S. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics, *Adv. Drug Deliv. Rev.* 59; 2007. Pg. 1015-1035.
39. Altinok A, Levi F, Goldbeter. A cell cycle automation model for probing circadian patterns of anticancer drug delivery, *Adv. Drug Delivery. Rev.* 59; 2009. Pg. 1036-1053.
40. Hori K, Suzuki M, Tanda S, Saito S, Shinzaki M, Zhang QH. Circadian variation of tumor blood flow in rat subcutaneous tumors and its alteration by angiotensin II induced hypertension, *Cancer Res* .52; 1992. Pg. 912-916.
41. Hori K, Zhang QH, Li HC, Saito S, Sato Y. Timing of cancer chemotherapy based on circadian variations in tumor tissue blood flow, *Int. J.Cancer* 65;1996. Pg. 360-364.
42. Tofler GH, Brezinski D, Schafer AI, Czeisler CA, Rutherford JD, Willich SN, Gleason RE, Williams GH, Muller JE. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death, *N Engl J. Med*, 316; 1987. Pg. 1514-1518.
43. Portaluppi F, Lemmer B. Chronobiology and chronotherapy of ischemic heart disease, *Adv. Drug Deliv. Rev.* 59; 2007. Pg. 952-965.
44. Smith DH, Neutel JM, Weber MA. A new chronotherapeutic oral drug absorption system for verapamil (CODAS-Verapamil) designed for once daily bedtime dosing optimizes blood pressure control in the morning. *Am J Hypertens*: 14; 2001. Pg. 14-9.
45. Kelsoe JR, Greenwood TA, Akiskal HS, Akiskal KK. The genetic basis of affective temperament and the bipolar spectrum. *Int. Clin. Psychopharmacol.* 28; 2012. Pg. e5-6.
46. Portaluppi F, Lemmer B. Chronobiology and chronotherapy of ischemic heart disease, *Adv. Drug Deliv. Rev* 59; 2007.pg. 952-965.
47. Waldhauser W. Circadian rhythms of insulin needs and actions, *Diab. Res. Clin. Pract.* 6; 1989. Pg. S17-S24.
48. Kashyap S, Bala R, Behl T. Understanding the Concept of Chronotherapeutics in the Management of Diabetes Mellitus. *Curr Diabetes Rev.* 2021;17(5):e221020187106. doi: 10.2174/1573399816666201022120825. PMID: 33092512.

49. Jones PJH, Schoeller DA. Evidence for diurnal periodicity in human cholesterol synthesis, *J. Lipid Res.* 31; 1990. Pg. 667-673.
50. Sudhop T, Reber M, Tribble D, Sapre A, Taggart W, Gibbons P, Musliner T, von Bergmann K, Lütjohann D. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. *J. Lipid Res.* 50; 2009. Pg. 2117-23.
51. Kumar VM. Sleep and sleep disorders, *Indian J. Chest Dis. Allied Sci.* 50; 2008. Pg. 129-136.
52. Barion A, Zee PC. A clinical approach to circadian rhythm sleep disorders. *Sleep Med.* 8; 2007. Pg. 566-77.
53. Hofstra WA, de Weerd AW. How to assess circadian rhythm in humans: a review of literature, *Epilepsy Behav.* 13; 2008. Pg. 438-444.
54. Poirel C, Ennaji M. Circadian aspects of epileptic behavior in comparative psychophysiology, *Psychol. Rep.* 68; 1991. Pg. 783-801.
55. Patil SV, Patil AD, Salunkhe KS, Chaudhari SR. Chronotherapeutically Design Colon Targeted Drug Delivery System: A Review. *Journal of Current Pharma Research.* 3; 2013. Pg. 923.
56. Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A. Sundowning and circadian rhythms in Alzheimer's disease, *Am. J. Psychiatry.* 158; 2001. Pg. 704-711.
57. Scheer FA, Shea TJ, Hilton MF, Shea SA. An endogenous circadian rhythm in sleep inertia results in greatest cognitive impairment upon awakening during the biological night. *J. Biol. Rhythms.* 23; 2008. Pg. 353-61.
58. Bruguerolle B, Simon N. Biologic rhythms and Parkinson's disease: a chronopharmacological approach to considering fluctuations in function, *Clin. Neuropharmacol.* 25; 2002. Pg. 14-201.
59. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment Guidelines. *Neurology.* 56; 2001. Pg. S1-88.
60. Haus E. Chronobiology of hemostasis and inferences for the chronotherapy of coagulation disorders and thrombosis prevention, *Adv. Drug Deliv. Rev.* 59; 2007. Pg. 966-984.
61. Takeda N, Maemura K. Circadian clock and vascular disease. *Hypertens. Res.* 33; 2010. Pg. 645-51.
62. Atkinson G, Jones H, Ainslie PN. Circadian variation in the circulatory responses to exercise: relevance to the morning peaks in strokes and cardiac events. *Eur. J. Appl. Physiol.* 108; 2010. Pg. 15-29.
63. Budkowska M, Lebiecka A, Marcinowska Z, Woźniak J, Jastrzębska M, Dołęgowska B. The circadian rhythm of selected parameters of the hemostasis system in healthy people. *Thrombosis research.* 182; 2019. Pg. 79-88.
64. Beauchamp D, Labrecque G. Chronobiology and chronotoxicology of antibiotics and aminoglycosides, *Adv. Drug Deliv. Rev.* 59; 2007. Pg. 896-903.
65. Richards GN, Cistulli PA, Ungar RG, Berthon-Jones M, Sullivan CE. Mouth leak with nasal continuous positive airway pressure increases nasal airway resistance. *Am. J. Respir. Crit. Care Med.* 154; 1996. Pg. 182-6.
66. Haus E. Chronobiology in the endocrine system, *Adv. Drug Deliv. Rev.* 59; 2007. Pg. 985-1014.
67. Hastings M, O'Neill JS, Maywood ES. Circadian clocks: regulators of endocrine and metabolic rhythms. *Journal of Endocrinology.* 195; 2007. Pg. 187-98.
68. Saigal N, Baboota S, Ahuja A, Ali J. Multiple pulse drug delivery systems: Setting a new paradigm for infectious disease therapy. *Expert opin. Drug Deliv.* 6; 2009. Pg. 441-452.
69. Lemmer B. Chronobiology, drug delivery and chronotherapeutics, *Adv. Drug Deliv. Rev.* 59; 2007. Pg. 825-827.
70. Barzegar-Jalali M, Siyahi-Shadbad M. Design and evaluation of delayed release osmotic capsule of acetaminophen, *Iran J. Pharma. Sci. Spring* 2; 2006. Pg. 65-72.

71. Linkwitz A, Magruder JA, Merrill S. Osmotically driven delivery device with expandable orifice for pulsatile delivery effect, US Patent 5,318,558; 1994.
72. Balaban SM, Pike JB, Smith JP, Baile CA. Osmotically driven delivery devices with expandable orifice for pulsatile delivery effect. US Patent 5,20,746 ;1993.
73. Niwa K, Takaya T, Morimoto T, Takada K. Preparation and evaluation of time controlled release capsule made of ethyl cellulose for colon delivery of drugs, *J. Drug Target*, 3; 1995. Pg. 83-89.
74. Mastiholimath VS, Dandagi PM, Jain SS, Gadad AP, Kulkarni AR. Time and pH dependent colon specific, pulsatile delivery of theophylline for nocturnal asthma. *Int. J. Pharm.* 328; 2007. Pg .49-56.
75. Arora S, Ali J, Ahuja A, Baboota S, Qureshi J. Pulsatile drug delivery systems :an approach for controlled drug delivery , *Indian J. Pharm . Sci*; May-June 2006. Pg. 295-300.
76. Bussemer T, Dashevsky A, Bodmeier R. A pulsatile drug delivery system based on rupturable coated hard gelatin capsules, *J. Control Release* 93; 2003 .Pg . 331-339.
77. Krogel I, Bodmeier R. Pulsatile drug release from an insoluble capsule body controlled by an erodible plug . *Pharm. Res.* 15; 1998. Pg. 474-481.
78. Mohamad A, Dashevsky A. pH-independent pulsatile drug delivery system based on hard gelatin capsules and coated with aqueous dispersion Aquacoat ECD, *Eur. J. Pharm. Biopharm.* 64; 2006. Pg .173-179.
79. Stevens HNE, Wilsons CG, Welling PG, Bakhshae M, Binns JS, Perkins AC. Evaluation of Pulsincap TM to provide regional delivery of dofetilide to the human GI tract . *Int. J . Pharm.* 236 ; 2002. Pg . 27-34.
80. Binns J, Stevens HNE, McEwen G, Pritchard FM, Brewer A, Clarke A, et al. The tolerability of multiple oral doses of pulsincapTM capsules in healthy volunteers . *J. Control. Release.* 38 ; 1996. Pg .151-158.
81. Pozzi F, Furlani P, Gazzaniga SS. THE TIME CLOCK system: a new oral dosage form for fast and complete release of drug after predetermined lag time, *J. Control. Release* 31; 1994. Pg. 99-108.
82. Wilding Ir, Davis SS, Pozzi F, Furlani P, Gazzaniga A. Enteric coated timed release systems for colonic targeting . *Int. J. Pharm.* .111 ;194. Pg. 99-102.
83. Gazzaniga A, Lamartino P, Maffione G, Sangalli ME. Oral delayed-release system fro colonic specific delivery. *Int. J. Pharm.* 2 ; 1994.Pg .77-83.
84. Maroni A, Zema L, Cerea, Sangalli ME. Oral pulsatile drug delivery system, *Expert poin. Drug Deliv.* 2; 2005. Pg. 2005.
85. Sangalli ME, Maroni A, Zema L, Busetti C, Giordano F, Gazzaniga. In vitro and in vivo evaluation of an oral system for time and / or site specific drug delivery ,*J. control . Release* .73; 2001. Pg .13-110.
86. Gazzaniga A, Giordano F, Sangalli ME, Zema L. Oral colon specific drug delivery : design strategies. *S T P Pharma. Prat.*4, ;1994a. Pg . 336-343.
87. Gazzaniga A, Maroni A, Sangalli ME, Zema L. Time-controlled oral delivery systems for colon targeting . *Expert Opin. Drug Deliv*; 2006. Pg . 583-597.
88. Takayama T, Goji T, Taniguchi T, Inoue A. Chemoprevention of colorectal cancer – experimental and clinical aspects. *J. Med . Invest* 56 ;2009. Pg .1-5.
89. Conte U, La Manna A, Colombo P. Tablet for pharmaceutical use able to release active substance at successive times, US Patent 4,865,849 ;1989.
90. Conte U, Giunchedi P, Maggi L, Sangalli ME, Gazzaniga A, Colombo P, La Manna A. Ibuprofen delayed release dosage forms: a proposal for the preparation of an in vitro/ invivo pulsatile system, *Eur. J. Pharm.*38; 1992. Pg .209-212.
91. Hermida RC, Ayala DE, Calvo C, Smolensky MH. Chronotherapy of hypertension : Administration time-dependent effects of treatment on the circadian pattern of blood pressure . *Adv. Drug Deliv. Rev.* 59; 2007. Pg . 923-993.

92. Roy p, Shahiwala A. Multiparticulate formulation to pulsatile drug delivery: Current Perspectives, *J. Control. Release* 134 ; 2004. Pg . 74-80.
93. Bussemer T, Bodmeier R. Multiparticulate pulsatile drug delivery systems, in : S. Benita (Ed), *Microencapsulation Methods and Industrial Application Second Edition* , CRC Press, Tylor and Francis Group, 6000 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487-2742 ;2006.
94. Maffione G, Lamartino P, Guglielmini G, Gazzaniga A. High-viscosity HPMC as a film-coating agent. *Drug Dev. Ind Pharm.*19; 1993. Pg .2043-2053.
95. Wilding IR, Davis SS, Bakhshae M, Stevens HNE, Sparrow RA, Brennan J. Gastrointestinal transit and systemic absorption of captopril from a pulsed-release formulation. *Pharm. Res.*9 ;1992. Pg .654-657.
96. Krogel I, Bodmeier R. Floating or pulsatile drug delivery systems based on coated effervescent cores, *Int. J. Pharm.* 187; 1999. Pg. 175-184.
97. Percel P, Vishnupad KS, Venkatesh GM. Timed pulsatile drug delivery systems, US Patent No. 6,627,223B ;2003.
98. Narisawa S, Nagata M, Danyoshi C, Yoshino H. An organic acid induced sigmoidal release system for oral controlled-release preparations. Part II: permeability enhancement of Eudragit RS coating led by the physiochemical interactions with organic acid, *J. Pharm. Sci.* 85 ; 1996 .Pg. 184-188.
99. Narisawa S, Nagata M, Danyoshi C, Yoshino H, Murata K, Hirakawa Y, Noda K. An organic acid- induced sigmoidal release system for oral controlled-release preparations, *Pharm. Res.* 11 ;1994. Pg .111-116.
100. Bodmeier R, Guo X, Sarabia RE, Skultety P. The influence of buffer species and strength on diltiazem HCl release from beads coated with aqueous cationic polymer dispersions, *Eudragit RS, RL30D*, *Pharm. Res.* 13 ;1996 .Pg . 52-56.
101. Krogel I, Bodmeier R. Pulsatile drug release from an insoluble capsule body controlled by an erodible plug. *Pharm. Res.* 15 ; 1998. Pg .474-481.
102. Ross AC, MacRae RJ, Walther M, Stevens HNE. Chronopharmaceutical drug delivery from a pulsatile capsule device based on programmable erosion . *J. Pharm. Pharmacol.* 52 ;2000. Pg .903-99.
103. Gohel MC, Sumitra GM. Modulation of active pharmaceutical material release from novel “tablet in capsule system” containing an effervescent blend . *J. Control . Release* .79; 2002. Pg .157-164.
104. McConville JT, Hodges LA, Jones T, Band JP, O’Mahony B, Lindsay B, et al. A Pharmacoscintigraphic study of three time-delayed capsule formulations in healthy male volunteers. *J. Pharm. Sci.*98 ; 2009. Pg .4251-4263.
105. Bruguerolle B, Lemmer B. Recent advances in chronopharmacokinetics : methodological problems. *Life science.* 52; 1993. Pg .1809-1824.
106. Nayak UY, Shavi GV, Nayak Y, Averinen RK, Mutalik S, Reddy SM, et al. Chronotherapeutic drug delivery for early morning surge in blood pressure: a programmable delivery system. *J. Control . Release* 136; 2009. Pg .125-131.
107. Chronopharmacokinetics: Current status . *Clin Pharmacokinet.*35. pg .83-94.
108. Davis ss. The design and evaluation of controlled release system for the gastro- intestinal tract. *J. Control Release*2; 1985. Pg . 27-38.
109. Gupta SK, Atkinson L, Theeuwes F, Wong P, Gilbert PJ, Longstreth J. Pharmacokinetics of verapamil from an osmotic system with delayed onset . *Eur. J. Pharm .Biopharm*, 42; 1996. Pg .74-81.
110. Rebuelto M, Ambros L, Rubio M. Daily Variations ceftriaxone pharmacokinetics in Rats: antimicrobial agent and chemotherapy. 47; 2003. Pg .809-812.
111. Michel lebrun, Louis Grenier, Pierrette Gourde, Michel g Bergeron, Gaston Labrecque and dennisbeauchamp. Effectiveness and toxicity of Gentamicin in an experimental model of pyelonephritis: effect of the time of administration . antimicrobe, agents and chemother.43; 1999. Pg .1020-1026.
112. Poondru S, Devaraj R, Boinpally R, Yamasani MR. Chronopharmacokinetics of sumatriptan in healthy human subjects. *J Pharm Pharmacol.*, 52; 2000. Pg . 1085-1090.

113. Cipolle RJ, Canafax DM, Rabatin J, Bowers Id; et al. Time – Dependent disposition of cyclosporine after pancreas transplantation, and application of chronopharmacokinetics to improve immunosuppression . pharmacotherapy ;1988. Pg .47-51.
114. Aurelie Premaud, Annick Rousseau, Mireille Gicquel, Sylvie Ragot, Jacqueline Manceau, Michel Laurentie et al. An Animal Model for the Study of chronopharmacokinetics of Drugs and Application to Methotrexate and Vinorelbine : Toxicology and Applied Pharmacology; 2002. 183.Pg .189-197.
115. Conte U, Colombo P, La Manna A, Sangalli ME, Giunchedi P. A new ibuprofen pulsed release oral dosage form. Drug Dev. Ind . Pharm. 15; 1989. Pg .2583-2596.
116. Marikki Halsas, Jaana Hietala, Peep Veski, Heidi Ju rjenson, Martti Marvola. Morning versus evening dosing of ibuprofen using conventional and time controlled release formulations . Int.J. Pharm. 189 ;1999. Pg .179-185.
117. Bussemer T, Otto I, Bodmeier R. Pulsatile drug-delivery systems . Crit. Rev. Ther. Drug Carrier Syst, 18; 2001. Pg . 433-458.
118. Maroni A, Zema L, Cerea M, Sangalli ME. Oral pulsatile drug delivery systems. Expert Opin. Drug Deliv. 2 ;2005. Pg .855-871.
119. Gazzaniga A, Palugan L, Foppoli A, Sangalli ME. Oral pulsatile delivery systems based on swellable hydrophilic polymers. Eur. J. Pharm. Biopharm. 68; 2008. Pg . 11-18.